戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              BMT alveolar macrophages (AMs) exhibited a defect in P.
2                                              BMT experiments revealed that BM-derived macrophages exp
3                                              BMT resulted in near complete replacement of host retina
4                                              BMT-derived microglia engraftment was significantly redu
5                                              BMT-exposed neonates had higher mean gestational age and
6                                              BMT-recipient mice receiving donor T cells with enhanced
7 study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lympho
8 ssion analysis in cerebral cortex of APOE3/3 BMT recipients showed reduced expression of tumor necros
9 luble and plaque Abeta compared with APOE3/3 BMT-recipient APPswe/PS1DeltaE9 mice.
10                  Eight months later, APOE4/4 BMT-recipient APPswe/PS1DeltaE9 mice had significantly i
11 ell engraftment with MGMT transgenic C57BL/6 BMT after BCNU treatment, demonstrating full reconstitut
12  Despite a difference in phagocytic ability, BMT AMs harbor a killing defect to both P. aeruginosa an
13 specially skin cancer, was observed in adult BMT-rescued DNA-PKcs(3A/3A) mice.
14 c allografts were performed at day 243 after BMT.
15 57BL/6 grafts was performed at day 358 after BMT.
16 -year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92).
17 oid organs, and target organs of aGvHD after BMT showed significantly reduced numbers of miR-181a-tra
18 l MR examinations performed before and after BMT was collected from each patient's records.
19  of low levels of proliferation 4 days after BMT.
20 present on donor dendritic cells (DCs) after BMT in the setting of myeloablative conditioning but is
21 cells (DCs) is markedly impaired early after BMT.
22 s may be responsible for relapse, even after BMT.
23                          NET formation after BMT was rescued both in vitro and in vivo with cyclooxyg
24 when reconstructing antiviral immunity after BMT, and highlight the mechanisms by which the adoptive
25         HLI surgery was performed 1 mo after BMT, after confirming complete engraftment of the recipi
26 r origin CD8(+) cells detected 1 month after BMT, and remained stable (85.5 +/- 11% mean donor origin
27 Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consi
28 ly severe non-GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling
29 l (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients w
30 tly associated with different survival after BMT for hematologic malignancies.
31 ted mortality, and/or overall survival after BMT.
32 nsion and suppressive function of Treg after BMT.
33 ver, specific depletion of donor Tregs after BMT also induced cGVHD, whereas adoptive transfer of Tre
34 vo expansion/maturation of donor Tregs after BMT.
35 itional on surviving the first 2 years after BMT, 5-year survival generally exceeds 70%.
36 ches in secondary lymphoid organs after allo-BMT and define a framework of early cellular and molecul
37 dministration of a VIP antagonist after allo-BMT is a promising safely therapeutic approach to enhanc
38 show that the development of GVHD after allo-BMT prevented NK-cell reconstitution, particularly withi
39 ntestinal epithelial cells (IECs) after allo-BMT resulted in decreased histone acetylation, which was
40 trol of cytomegalovirus infection after allo-BMT was also impaired during GVHD.
41  cellular source of Notch ligands after allo-BMT.
42 aintained their expansion in irradiated allo-BMT recipients, as well as their in vivo and ex vivo cyt
43 window after transplantation in a mouse allo-BMT model.
44 ti-CMV immunity in murine recipients of allo-BMT.
45 nd CD8(+) T cells using mouse models of allo-BMT.
46 cal blockade of VIP-signaling protected allo-BMT recipients from lethal murine CMV (mCMV) infection,
47 wing allogeneic bone marrow transplant (allo-BMT) is controlled by donor-derived cellular immunity.
48 fter allogeneic bone marrow transplant (allo-BMT).
49 Allogeneic bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancie
50 allogeneic bone marrow transplantation (allo-BMT).
51 allogeneic bone marrow transplantation (allo-BMT).
52                                   Allogeneic BMT and its major complication, graft-versus-host diseas
53  withdraw immunosuppression after allogeneic BMT should be made with caution.
54 MT, in the presence of GVHD after allogeneic BMT, CMV induced a striking cytopathy resulting in unive
55 ptimizing vaccine responses after allogeneic BMT.
56 pient mice that have undergone an allogeneic BMT [SP-A(-/-)alloBMT] or SP-A-sufficient recipient mice
57     Five patients who received an allogeneic BMT for the treatment of hematological diseases develope
58 pient mice that have undergone an allogeneic BMT had no significant differences in lung pathology; ho
59 nt in SP-A that have undergone an allogeneic BMT have a greater incidence of GI GVHD that is associat
60 pient mice that have undergone an allogeneic BMT) or C57BL/6 (H2b; SP-A-deficient recipient mice that
61 sease risk across histologies and allogeneic BMT regimens.
62 ablative TLI/ATS conditioning and allogeneic BMT, induce PD-1 ligand-dependent donor nTreg proliferat
63 P3(+) Treg cell numbers following allogeneic BMT by two pathways: instability of natural Treg (nTreg)
64 ammation and improve outcomes for allogeneic BMT recipients.
65 monstrate, using murine models of allogeneic BMT, that type 2 innate lymphoid cells (ILC2s) in the lo
66                                     Although BMT increases the life span of patients with MPS IH, mus
67 as well as in the in vivo MLL-rearranged AML BMT model coupled with treatment of "5 + 3" (i.e. DOX pl
68 uated two selective NR2B NAMs, CP101,606 and BMT-108908, along with the nonselective NMDA antagonists
69 nstrated by in vitro proliferation assay and BMT.
70 (H-2(d)) hosts were administered TLI/ATS and BMT from WT or STAT6(-/-) C57BL/6 (H-2(b)) donors.
71 analysis, DFS did not differ between CBT and BMT recipients.
72 mes after both HLA-identical sibling CBT and BMT.
73 strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic s
74 TS + BMT versus total body irradiation/ATS + BMT.
75 Jalpha18(-/-) BALB/c recipients of TLI/ATS + BMT restored day-6 donor Foxp3(+) nTreg proliferation an
76 D11c(+)) were enriched early after TLI/ATS + BMT versus total body irradiation/ATS + BMT.
77                              After TLI/ATS + BMT, Gr-1(low)CD11c(+) MDCs and Gr-1(high)CD11c(neg) mye
78 pha18(-/-) BALB/c recipients after TLI/ATS + BMT.
79 ouse model, Tcm therapy following autologous BMT led to significant survival prolongation, with 30% t
80 orldwide who received cyclophosphamide-based BMT regimens for leukemias between 1990 and 2007.
81 -based (RSP), 2) non-sputum Biomarker-based (BMT), 3) triage test followed by confirmatory test (TT),
82                               One day before BMT, rats were treated with varying doses of total body
83 actobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predomina
84                                    beta2ARKO BMT mice displayed 100% mortality resulting from cardiac
85                                    beta2ARKO BMT mice displayed severely reduced post-MI cardiac infi
86 rbidity, coupled with a long latency between BMT and the development of chronic health conditions nec
87 clinically relevant approach to perform both BMT and VCA simultaneously was evaluated.
88 elated retinal degeneration was mitigated by BMT.
89 eveloped and evaluated the radiotracer (11)C-BMT-136088 (1-(4'-(3-methyl-4-(((1(R)-(3-(11)C-methylphe
90                                Results:(11)C-BMT-136088 baseline VT was 1.83 +/- 0.16 (MA1, n = 5) or
91                    Specific binding of (11)C-BMT-136088 can be reliably measured to quantify LPA1 in
92 ntration leading to a 50% reduction of (11)C-BMT-136088 specific binding were 73 +/- 30 nmol/kg and 2
93         For the self-saturation study, (11)C-BMT-136088 VND and BPND were estimated to be 0.9 +/- 0.0
94 out immunosuppression, whereas non-Treg cell BMT recipients rejected delayed donor kidneys within 3 t
95  In contrast, 2 of 5 recipients of Treg cell BMT that were evaluable displayed chimerism in all linea
96 nce can be successfully induced with delayed BMT to previous recipients of kidney transplantation or
97          The tolerance achieved with delayed BMT was donor specific as confirmed by acceptance of don
98  conjunction with allogeneic T-cell-depleted BMT could be of particular benefit in patients with B-ce
99                   BaMn3Ti4O14.25, designated BMT-134, possesses the signature channel-like hollandite
100 ects in P. aeruginosa internalization as did BMT AMs.
101 cant SNPs replicated at P < .05 in DISCOVeRY-BMT.
102  associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveyi
103  In addition, infusion of extra Tregs during BMT results in a delayed reconstitution of T-cell compar
104 d by infusing extra Foxp3(GFP+) Tregs during BMT.
105 g a rotarod test, we demonstrated that early BMT greatly delayed the motor impairment in the mutant m
106 was confirmed in MHC-mismatched experimental BMT.
107  Cancer Therapy-Bone Marrow Transplant (FACT-BMT) were received from 109 ex-thalassemia patients who
108                During the year that followed BMT, all patients presented with GVHD.
109 re, we studied CAR T-cell function following BMT using an immunocompetent murine model of minor misma
110 rived MHC class I and II molecules following BMT.
111                                          For BMT survivors, screening recommendations must incorporat
112  ideation was rare (1.9% for DBS vs 0.9% for BMT; Fisher's exact p=0.61).
113 nsive review articles, clinicians caring for BMT recipients continue to field frequently asked questi
114                In patients otherwise fit for BMT, the results support consideration of this approach
115 on, but only CD8(+) T cells are required for BMT rejection.
116 d NET formation in neutrophils isolated from BMT mice or HSCT patients.
117                 Compared with patients given BMT, CBT recipients were significantly younger (median a
118 udy evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years.
119                                    NMA haplo-BMT with post-transplantation cyclophosphamide has encou
120 ears, who received NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide
121 tical blood or marrow transplantation (haplo-BMT) have expanded the donor pool.
122 oietic lineages 28 days after haploidentical BMT with 69.3 +/- 14.1%, 75.6 +/- 20.2%, and 88.5 +/- 11
123  CD8(+) cells) 6 months after haploidentical BMT.
124 uCi (90)Y-DOTA-30F11, CY, and haploidentical BMT were cured and lived >200 days.
125 atifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this transplantatio
126 of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hematologic maligna
127                  RIT-mediated haploidentical BMT without TBI may increase treatment options for aggre
128                                     However, BMT may be a particularly compelling setting to test CSC
129 orter (-7.23 days, 95% CI: -10.64, -3.83) in BMT-exposed versus MMT-exposed neonates.
130 ave shown trends of reduced aspergillosis in BMT patients; however, no survival benefits were seen, a
131 e found increased MHC class II expression in BMT-derived microglia and decreased oxidative damage in
132  GVHD, sustain GVT, and prevent mortality in BMT.
133 re reduced (61.0% and 44.1% respectively) in BMT-recipient AD mice, which had 20.8% more retinal gang
134 nate immune function and oxidative stress in BMT recipient mice.
135        Transplantation of whole bone marrow (BMT) as well as ex vivo-expanded mesenchymal stromal cel
136 lar survivals to those seen with HLA-matched BMT.
137 ity complex (MHC)-mismatched and MHC-matched BMT following conditioning with lethal and sublethal irr
138 ing a minor histocompatibility Ag-mismatched BMT (B6 --> B6 x C3H.SW) followed by adoptive transfer o
139  major histocompatibility complex mismatched BMT with or without Treg cell infusion.
140 LI/ATG/alkylator regimens for MHC-mismatched BMT for hemoglobinopathies.
141 ic bone marrow transplant (BMT) mouse model, BMT mice with a reconstituted hematopoietic system displ
142 Here, we describe our approach to monitoring BMT survivors for risk-based screening and early detecti
143 ched sibling (matched sibling donors [MSDs]) BMT in 66 patients.
144 e initiation phase of acute GVHD in a murine BMT model.
145                  Furthermore, in aged murine BMT recipients, the contribution of the MLNs to the gene
146 ed for its ability to prevent GVHD in murine BMT models across minor or major histocompatibility barr
147 ration was possible in an MHC-matched murine BMT model (B10.BR-->CBA) with a CBA-derived myeloid leuk
148                    We observed that neonatal BMT was effective at restoring alpha-l-iduronidase activ
149 d Marrow Transplant Clinical Trials Network (BMT CTN) 0802, a phase 3 multicenter randomized double-b
150 d Marrow Transplant Clinical Trials Network (BMT CTN) phase 2 trial conducted from 2008 to 2014 enrol
151               Interestingly, the addition of BMT further increased the lifespan of treated mice and l
152 e COX-2 gene is hypomethylated in the AMs of BMT mice compared with control.
153 st disease remain important complications of BMT.
154 ysis model and estimated summary measures of BMT versus MMT on several outcomes.
155     Using well-characterized mouse models of BMT, we have studied the effects of AAT on GvHD severity
156 omised to DBS surgery (n=121) or 6 months of BMT (n=134).
157 HD, preserve GVT, and improve the outcome of BMT.
158 mune conditioning may improve the outcome of BMT.
159 educed intensity regimens have high rates of BMT rejection.
160                   Since the first studies of BMT in the late 1980s, a number of conditioning regimens
161 e only minimally responsive if the timing of BMT delays, suggesting already irreversible bone damage.
162                                 Treatment of BMT or HSCT neutrophils with phorbol 12-myristate 13-ace
163 n 2 years and 98% occurred within 3 years of BMT.
164 tment, using the CSF-1R antagonist GW2580 or BMT from CCR2-deficient donors, reduced perineurial inva
165                                        Other BMT options include unrelated cord blood or mismatched f
166  26.1) in 16 thalassemia patients to perform BMT using phenotypically HLA-identical or 1-antigen-mism
167                   To test this, we performed BMT in APPswe/PS1DeltaE9 double transgenic mice using gr
168                                  In the PGIA BMT model, after an initial predominance of host Tregs,
169 and COX-2 expression is elevated in AMs post-BMT.
170 ) T cells increased FoxP3(+) Treg cells post-BMT and prevented lethality, suggesting that the consequ
171 , including T cells, for up to 335 days post-BMT.
172 5), and miR-155 expression is decreased post-BMT.
173 ed innate immunity and PGE(2) elevation post-BMT are due to hypomethylation of the COX-2 gene, which
174  Because TGF-beta1 is elevated in lungs post-BMT, we tested whether TGF-beta1 could promote expressio
175  same BMT donor) was performed 4 months post-BMT without immunosuppression to assess for robust donor
176 ving an impaired innate immune response post-BMT.
177                              Five weeks post-BMT, mice were necropsied, and lung and GI tissue were a
178 s must incorporate risks associated with pre-BMT therapy as well as risks related to transplant condi
179                                     Prenatal BMT versus MMT may improve neonatal outcomes, but bias m
180 nts who were conditioned but did not receive BMT.
181 II-III of the Pesaro classification received BMT (44%) compared with CBT (39%, P < .01).
182 cts were 515 neonates whose mothers received BMT and 855 neonates whose mothers received MMT and who
183 m, was achieved in the animals that received BMT without Treg cells (N = 3).
184      Patients with EC (N = 276) who received BMT were analyzed.
185              Compared to the group receiving BMT, the combined DBS group had significantly greater me
186        In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66
187         Renal transplantation (from the same BMT donor) was performed 4 months post-BMT without immun
188         The issues of how and when to screen BMT survivors for therapy-related complications and exac
189 s 3 thalassemia received HLA-matched sibling BMT following either the original protocol (26 patients)
190      These studies suggest that simultaneous BMT and VCA may establish indefinite allograft survival
191                         Following STAT6(-/-) BMT, donor nTregs demonstrated no loss of proliferation
192                                   Subsequent BMT is itself an additional and distinct immunizing even
193 ansfused platelet products induce subsequent BMT rejection.
194 cipient mice that have undergone a syngeneic BMT or SP-A-sufficient recipient mice that have undergon
195 cipient mice that have undergone a syngeneic BMT) mice.
196  infection was self-limiting after syngeneic BMT, in the presence of GVHD after allogeneic BMT, CMV i
197 otency to those administered after syngeneic BMT.
198 -/-)) mice underwent allogeneic or syngeneic BMT with cells from either C3HeB/FeJ (H2k; SP-A-deficien
199 elopment of autoimmune disorder in syngeneic BMTs.
200                             We conclude that BMT at a very early stage in life markedly reduces signs
201                                We found that BMT suppressed the reduced myelination and the increased
202    These data are truly striking, given that BMT alone is ineffective, yet it synergizes with CNS-dir
203 eta in experimental AD, we hypothesized that BMT would mitigate retinal neurotoxicity through decreas
204        These data offer the possibility that BMT might provide the first therapy for MLIV.
205        Together, these findings suggest that BMT-derived APOE3-expressing cells are superior to those
206 t to prolong renal allograft acceptance: the BMT/renal mean survival time (MST, 76 days) was not sign
207 t peripheral donor cells originated from the BMT and not from the VCA.
208  reliable change from data obtained from the BMT group, the combined DBS group also displayed higher
209 ins, a significantly higher rate than in the BMT group (3%).
210 age treatment plays a lesser role,(1) in the BMT population, approximately 8% of all patients (or 36%
211 tates life-long risk-based monitoring of the BMT survivors.
212  to DBS surgery versus best medical therapy (BMT); and (2) randomised to subthalamic nucleus (STN) ve
213 rolled study comparing best medical therapy (BMT, n=116) and bilateral deep brain stimulation (DBS, n
214 itive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses.
215 uction strategy with mixed chimerism through BMT in prior kidney or VCA recipients.
216                                        Thus, BMT is neuroprotective in age-related as well as AD-rela
217 mg, 95% CI: -7.26, 0.07) in those exposed to BMT.
218 we review whether CSCs may have relevance to BMT.
219 and those undergoing bone marrow transplant (BMT) are at greatest risk for contracting IFDs.
220 ths before and after bone marrow transplant (BMT) from his RSV-immune father.
221 d outcomes after blood or marrow transplant (BMT) have been conducted.
222 nt murine allogeneic bone marrow transplant (BMT) models.
223  Using our syngeneic bone marrow transplant (BMT) mouse model, BMT mice with a reconstituted hematopo
224 reported that murine bone marrow transplant (BMT) neutrophils overexpress cyclooxygenase-2, overprodu
225 receiving allogeneic bone marrow transplant (BMT) with minimal conditioning.
226 ceiving a bone marrow and renal transplant ("BMT/renal") and one receiving only a renal transplant.
227             Furthermore, BM transplantation (BMT) from either COX-2-deficient or mPGES-1-deficient mi
228  we generated 2 chimeric BM transplantation (BMT) models where both young green fluorescent protein (
229 d at 4 time points after BM transplantation (BMT).
230 te GVHD after allogeneic BM transplantation (BMT).
231 ogous bone marrow stem cell transplantation (BMT) were evaluated.
232 tolerance after bone marrow transplantation (BMT) across major histocompatibility complex (MHC) dispa
233 rance following bone marrow transplantation (BMT) across MHC barriers via recipient invariant NKT (iN
234 betaARKO) or WT bone-marrow transplantation (BMT) and after full reconstitution underwent MI surgery.
235 wing allogeneic bone marrow transplantation (BMT) and is characterized by tissue fibrosis manifesting
236 imerism through bone marrow transplantation (BMT) are currently being pursued.
237 allogeneic blood and marrow transplantation (BMT) as a curative therapy for hematological malignancie
238 g/replating and bone marrow transplantation (BMT) assays showed that Alox5 exhibited a moderate anti-
239 EW: Despite blood or marrow transplantation (BMT) being arguably the most active modality against hem
240  < .0001) after bone marrow transplantation (BMT) by inhibiting the initiation phase of acute GVHD in
241 rative and only bone marrow transplantation (BMT) can correct the underlying enzymatic defect.
242        Neonatal bone marrow transplantation (BMT) could offer a novel therapeutic opportunity for gen
243 ing a series of bone marrow transplantation (BMT) experiments in transgenic mice expressing single mu
244                 Bone marrow transplantation (BMT) for class 3 patients with thalassemia is challengin
245 psing following bone marrow transplantation (BMT) has a dismal prognosis.
246         Indeed, bone marrow transplantation (BMT) has its genesis in rodent models dating back to the
247 ipients of blood and marrow transplantation (BMT) have been published by 3 major societies: American
248 es (AMs), after bone marrow transplantation (BMT) have impaired host defense against Gram-negative Ps
249 lowing congenic bone marrow transplantation (BMT) in a proteoglycan-induced arthritis (PGIA) mouse mo
250 ne therapy with bone marrow transplantation (BMT) in the INCL mouse.
251 wing allogeneic bone marrow transplantation (BMT) induce graft-versus-host (GVH) responses, but their
252 rs, HLA-matched bone marrow transplantation (BMT) is curative.
253                 Bone marrow transplantation (BMT) is the other therapeutic option: a matched sibling
254             Blood or marrow transplantation (BMT) is used with curative intent for hematologic malign
255 re we show that bone marrow transplantation (BMT) of PARP-knockout (PARPKO) cells to wild-type mice p
256 ficantly affect bone marrow transplantation (BMT) outcomes.
257                 Bone marrow transplantation (BMT) performance can be limited by a lack of ideal donor
258         Because bone marrow transplantation (BMT) results in decreased cerebral Abeta in experimental
259 s of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-ver
260 n of allogeneic bone marrow transplantation (BMT) that involves the gastrointestinal (GI) tract and l
261 , which require bone marrow transplantation (BMT) to prevent early mortality.
262 created through bone marrow transplantation (BMT) using wild-type and CXCR2-knockout mice, yielding s
263  Haploidentical bone marrow transplantation (BMT) with 300 muCi (90)Y-anti-CD45 RIT and CY, without T
264 loidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide
265 ic by combining bone marrow transplantation (BMT) with kidney transplantation following non-myeloabla
266 fter allogeneic bone marrow transplantation (BMT), an effective therapy for hematological malignancie
267 fter allogeneic bone marrow transplantation (BMT), particularly in the presence of graft-versus-host
268     Here we use bone marrow transplantation (BMT), total body irradiation (TBI) and abdominal irradia
269 urine models of bone marrow transplantation (BMT), we find that MHCII(-/-)-->wild-type BMT developed
270 ents undergoing bone marrow transplantation (BMT).
271 r relapse after bone marrow transplantation (BMT).
272 t disease after bone marrow transplantation (BMT).
273 ution following bone marrow transplantation (BMT).
274 fter allogeneic bone marrow transplantation (BMT).
275 fects following bone marrow transplantation (BMT).
276  reported after bone marrow transplantation (BMT).
277 sirable goal in bone marrow transplantation (BMT).
278 allogeneic blood and marrow transplantation (BMT).
279 c recipients of bone marrow transplantation (BMT).
280 fter allogeneic bone marrow transplantation (BMT).
281 the efficacy of bone marrow transplantation (BMT).
282 wing allogeneic bone marrow transplantation (BMT).
283 CBT, n = 96) or bone marrow transplantation (BMT, n = 389).
284 onor bone marrow and cord blood transplants (BMT and CBT) for severe beta thalassemia (SBT) and sickl
285        We performed bone marrow transplants (BMT) from green fluorescent protein-expressing human APO
286 renatal buprenorphine maintenance treatment (BMT) versus methadone maintenance treatment (MMT) may im
287                    A phase 3 clinical trial (BMT CTN 0402) comparing tacrolimus/sirolimus (Tac/Sir) v
288 n (BMT), we find that MHCII(-/-)-->wild-type BMT developed disease, with defective development of inn
289 llows thalassemia patients to safely undergo BMT from RDs who are not HLA-matched siblings, with tran
290                                        Using BMT (with unit cost of US$2-4) would cost US$70-121 mill
291                                         When BMT recipients were given MMC6-presensitized CD8(+)Vbeta
292  to wild-type mice protects against, whereas BMT of wild-type cells to PARPKO mice, which are normall
293 ts of unbiased genome-wide associations with BMT clinical outcomes given the ultimate goal of improvi
294 /5-mediated gene therapy in combination with BMT provides an unprecedented increase in lifespan as we
295 e replacement of host retinal microglia with BMT-derived cells and normalized total AD retinal microg
296                     Fewer women treated with BMT used illicit opioids near delivery (risk ratio=0.44,
297                       Interestingly, aged wt BMT recipients also had significantly more neurons (25.4
298 pared with approximately 20% mortality in WT BMT mice.
299 -MI survival rates comparable to those in WT BMT mice.
300                   In adult p75KO with the WT-BMT, proliferative (Ki67(+)) cells were detected only by

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top